Calcineurin inhibitors (CNI) have significantly reduced the incidence of acute rejection. Nephrotoxicity however may contribute to long term allograft daysfunction. Myeophenolate mofetil (MMF) may allow cyclosporine (CSA) dose reduction without increasing the risk of rejection. In seventy-eight living renal transplant patients with renal dysfunction we studied the effect of CSA dose reduction associated with MMF on renal function and cardiovascular risk profile. We reduced the cyclosporine dose from mean 3.5 ± 0.94 mg/kg/d to 2 ± 0.51 mg/kg/d P< 0.0001. Mean follow-up was 22.99 ± 8.98 weeks. The reduction of CSA was associated with a decrement of median serum creatinine from 1.7 ± 0.99 mg/dl to 1.3 ± 0.52 mg/dl , P< 0.0001.We found improvement in lipid profile mean cholesterol level from 212.73 ± 41.72 to 199.69 ± 37.33 , P< 0.002. Mean triglyceride from 195.28 ± 92.21 to 167.64 ± 66.82, P < 0.003, mean uric acid from 6.81 ± 1.63 to 6.49 ± 1.52 P = 0.06, reduction in systolic blood pressure from 131.41± 21.62 to 126.65 ± 13.64, P< 0.01 reduction in diastolic blood pressure from 82. 82 ± 13.15 to 79.88 ± 8.3, P< 0.03. The addition of MMF allows a reduction of CSA without increased acute rejection. Improve renal function, dyslipidemia, hypertension and without effect on hyperuricemia.